Reference
Government of Canada. Summary Safety Review - JAKAVI (ruxolitinib) - Assessing the potential risk of drug interactions with P-glycoprotein (P-gp) substrates (including rosuvastatin). Internet Document : 9 Oct 2018. Available from: URL: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00212
Rights and permissions
About this article
Cite this article
Health Canada assesses risk of drug interactions with Jakavi. Reactions Weekly 1724, 1 (2018). https://doi.org/10.1007/s40278-018-52980-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-52980-6